Hybridoma Technology Platform
CD BioSciences's hybridoma technology platform mass-produces monoclonal antibodies (mAbs) relevant to plant protein research from hybridoma cells that survive long periodsin vitro and secrete immune proteins.
Technology Discovery
In 1975, Milstein and Köhler developed the hybridoma technology for obtaining cells that could continuously produce mAbs. This discovery unlocked enormous potential for biological research. Unlike polyclonal antibodies, mAbs recognize only one specific antigenic epitope. This high degree of selectivity allows mAbs to recognize, trace, quantify, or target proteins of interest from complex biological mixtures.
Figure 1. Diagram showing the production of monoclonal antibodies. (Mitra, S., & Tomar, P. C., 2021)Principle of Hybridoma Technology
mAbs are secreted by a single B-lymphocyte, which cannot survive for long periodsin vitro and produce large quantities of antibodies. While myeloma cells can multiply indefinitelyin vitro but cannot secrete antibodies. By fusing both cells, the resulting hybrid cells can secrete antibodies and proliferate indefinitely. Culturing the hybridoma cells will yield mAbs.
Process
Our Screening and Purification Methods
Hybridoma screening technologies
| Technologies | Screening methods | Efficiency |
| Fluorescence-activated cell sorting (FACS) | Flow cytometry analyzer | >300,000 hybridoma clones/day |
| Microfluidic fluorescence-activated droplet sorting (FADS) | Flow cytometry analyzer | >300,000 hybridoma clones/day |
Antibody purification methods
| Production method | Estimated monoclonal antibody production |
| Hybridoma culture supernatant (in vitro) | 1~3 mg/mL |
| Recombinant antibody expression (in vitro) | 1~100 mg/mL, concentration varies greatly with mAbs and expression system. |
| Ascites (in vivo) | 2.5~10 mg/mL |
Advantages and Limitations
Advantages
- Technology development has matured and is widely recognized.
- Lower cost of technology development.
Limitations
- Longer preparation time and poor reproducibility.
- Low rate of fusion between splenocytes and myeloma cells.
- Inability to prepare antibodies against non-immunogenic and highly toxic antigens.
- Unstable production of hybridoma cells with large batch-to-batch variation.
Why Choose CD BioSciences's Hybridoma Technology Platform
Hybridoma technology is a cost-effective, highly optimized, and valuable platform for monoclonal antibody generation. We are confident that based on your application, Lifeasbile's hybridoma technology platform will produce customized antibodies for you. If you have requirements on plant antibody development, please feel free to contact us!
Reference
- Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal, genetic engineering & biotechnology. 19(1), 159.
For research use only, not for clinical use.